MXCT(MaxCyte, Inc.) 的财务报表:医疗保健,医疗器械。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $33.89M | $44.26M | $41.29M | $38.63M | $33.03M |
| 毛利润 | $30.25M | $39.16M | $36.55M | $31.53M | $26.80M |
| 营业利润 | −$18.19M | −$27.36M | −$48.30M | −$51.20M | −$51.90M |
| 净利润 | −$19.08M | −$23.57M | −$37.92M | −$41.05M | −$44.63M |
| 经营现金流 | −$10.68M | −$14.78M | −$21.69M | −$27.61M | −$34.41M |
| 自由现金流 | −$14.51M | −$33.26M | −$25.39M | −$29.26M | −$36.18M |
| 摊薄每股收益 | $-0.21 | $-0.23 | $-0.37 | $-0.39 | $-0.42 |